Banna GL, Di Quattro R, Malatino L, Fornarini G, Addeo A, Maruzzo M, Urzia V, Rundo F, Lipari H, De Giorgi U, Basso U. Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy.
Clin Transl Oncol 2020;
22:2130-2135. [PMID:
32232716 DOI:
10.1007/s12094-020-02337-3]
[Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 03/12/2020] [Indexed: 12/23/2022]
Abstract
PURPOSE
To identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).
METHODS/PATIENTS
We explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.
RESULTS
NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).
CONCLUSIONS
NLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.
Collapse